Identification of a predictive biomarker for the beneficial effect of a Kampo (Japanese traditional) medicine keishibukuryogan in rheumatoid arthritis patients

Kampo (Japanese traditional herbal) medicines are now ethically used in Japan as pharmaceutical grade prescription drugs. However, there are distinct groups of responders and non-responders to Kampo medicines. We searched for biomarker candidates to discriminate responders from non-responders to kei...

Full description

Saved in:
Bibliographic Details
Published in:Clinical biochemistry 2007-10, Vol.40 (15), p.1113-1121
Main Authors: Ogawa, Kazuo, Kojima, Tetsuko, Matsumoto, Chinami, Kamegai, Satoshi, Oyama, Takuya, Shibagaki, Yukari, Muramoto, Hiroshi, Kawasaki, Tetsuo, Fujinaga, Hiroshi, Takahashi, Kozo, Hikiami, Hiroaki, Goto, Hirozo, Kiga, Chizuru, Koizumi, Keiichi, Sakurai, Hiroaki, Shimada, Yutaka, Yamamoto, Masahiro, Terasawa, Katsutoshi, Takeda, Shuichi, Saiki, Ikuo
Format: Article
Language:English
Subjects:
Adult
Aged
Amino Acid Sequence
Arthritis, Rheumatoid - diagnosis
Arthritis, Rheumatoid - drug therapy
Biomarkers - analysis
Cross detector
Drugs, Chinese Herbal - administration & dosage
Drugs, Chinese Herbal - therapeutic use
Female
Haptoglobin
Humans
Kampo medicine
Keishibukuryogan
Male
Medicine, Chinese Traditional
Medicine, Kampo
Middle Aged
Models, Theoretical
Molecular Sequence Data
Peak separability analysis
Phytotherapy
Prognosis
Protein Array Analysis
Responder
SELDI–TOF MS
Sensitivity and Specificity
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Kampo (Japanese traditional herbal) medicines are now ethically used in Japan as pharmaceutical grade prescription drugs. However, there are distinct groups of responders and non-responders to Kampo medicines. We searched for biomarker candidates to discriminate responders from non-responders to keishibukuryogan (KBG); one of the most frequently used Kampo medicines. A combination of SELDI technology and a decision tree analysis with proprietary developed bioinformatics tools was applied to 41 (32 for tree construction and 9 for validation test) plasma samples obtained from rheumatoid arthritis (RA) patients. A candidate biomarker protein was identified using LC–MS/MS. The constructed tree with measurable reliability contained only a single peak which was identified as haptoglobin alpha 1 chain (Hpα1). Hpα1 is a biomarker candidate for discriminating responders from non-responders to KBG treatment for RA. The present results may open the way to the establishment of “evidence-based” complementary and alternative medicine.
ISSN:0009-9120
1873-2933
DOI:10.1016/j.clinbiochem.2007.06.005